Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Immunic Therapeutics has raised $400.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Immunic Therapeutics's investors include RA Capital Management, HTGF (High-Tech Gruenderfonds), Vivo Capital, Janus Henderson Investors, TCG Crossover.
Immunic Therapeutics is headquartered in New York, United States.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Immunic Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunic Therapeutics — Funding & Investors." VCBacked, February 13, 2026, https://www.vcbacked.co/company/immunic-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Immunic Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/immunic-therapeutics
{{cite web |title=Immunic Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/immunic-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated